How Biotech Startups Use AI to Personalize Cancer Vaccines

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

How Biotech Startups Use AI to Personalize Cancer Vaccines

無料で聴く

ポッドキャストの詳細を見る

Episode 33 of Biotech Business with Fexingo: Lucas and Luna dive into the emerging field of personalized cancer vaccines. They focus on a specific case: how the startup Neon Therapeutics (now part of BioNTech) developed a neoantigen vaccine pipeline using AI to predict which mutations on a patient's tumor are most likely to trigger an immune response. The hosts walk through the key number: a phase 1 trial showed that 60% of patients with advanced melanoma had a T-cell response against their own tumor's neoantigens after receiving a personalized vaccine. Lucas explains the computational challenge—analyzing a patient's whole-exome sequencing data within weeks—and how platforms like Moderna's mRNA-4157 are now combining vaccines with checkpoint inhibitors. Luna asks tough questions about scalability, manufacturing costs (currently estimated at $100,000–$200,000 per dose), and whether the model can work for solid tumors beyond melanoma. They also touch on the FDA's recent guidance on neoantigen vaccines issued in March 2026. This episode is a deep look at how AI, genomics, and immunotherapy are converging to make truly individualized medicine a commercial reality. #PersonalizedCancerVaccines #Neoantigens #AIinBiotech #NeonTherapeutics #BioNTech #Moderna #CheckpointInhibitors #Melanoma #Immunotherapy #WholeExomeSequencing #PrecisionMedicine #ClinicalTrials #FDA #Business #Technology #FexingoBusiness #BusinessPodcast #BiotechBusiness Keep every episode free: buymeacoffee.com/fexingo

まだレビューはありません